Innovent announces 2nd BTD by NMPA for Olverembatinib for treatment of patients with SDH-deficient GIST

Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors

AstraZeneca receives CDSCO approval for Tremelimumab combination in India

Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)

Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy

Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada

Synexa Joins CEPI in advancing global epidemic preparedness and response

Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness

Kristin Judge Joins Emmes as Chief Growth Officer

Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies

Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.

Takeda to strengthen health system for rare diseases in India

These initiatives aim to improve access to healthcare for rare disease patients

USFDA approves Astellas' Veozah’ for treatment of vasomotor symptoms due to menopause

VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause

Takeda pledges support to HAE patients through its ‘Sunrise patient support program’

Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support

FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS

Lucid-MS is a new drug candidate for the treatment of multiple sclerosis